ライフサイエンスコーパス: CVP

1 CVP was measured in the same manner by maintaining PPP a

2 d less frequently in patients who achieved a CVP <8 mm Hg (p = 0.01).

3 I, 1.4-4.6]; pooled specificity, 76%), but a CVP greater than the threshold made fluid responsiveness

4 alysis of MR patients, minimal disease after CVP was a favorable prognostic factor.

5 e correlations were observed between AWP and CVP and between PPP and CVP (P < 0.001).

6 BP and CVP were not significantly different between the 2 pacin

7 were higher in COI patients, whereas BP and CVP were similar in the two groups.

8 During tilt, BP did not change and CVP fell by the same extent in the 2 groups; the increas

9 0 min) also significantly increased PCWP and CVP, and abolished the beneficial preload effect of L-NM

10 rved between AWP and CVP and between PPP and CVP (P < 0.001).

11 The mean difference between PVP and CVP was 0.4 mm Hg and between PVP and pulmonary capillar

12 PVP and CVP were found to be highly correlated (r=0.947), while

13 inimum CSA with tidal breathing at baseline (CVP nl) were intermediate.

14 er three conditions of CVP: (1) at baseline (CVP nl) with patients lying supine; (2) at decreased CVP

15 s were combined, the overall r value between CVP and PCWP was 0.92.

16 regulator of cardiovascular progenitor cell (CVP) specification.

17 All 30 patients enrolled completed CVP as well as tositumomab and (131)I-tositumomab therap

18 -anthracycline-containing regimen comprising CVP followed by one cycle of tositumomab and (131)I-tosi

19 est that in the assessed thermal conditions, CVP appropriately tracks left ventricular filling pressu

20 In contrast, CVP neuronal inhibition blocked cocaine-primed, but not

21 patients lying supine; (2) at decreased CVP (CVP-) by inflating blood pressure cuffs to 40 mm Hg on b

22 m Hg on both legs; and (3) at increased CVP (CVP+) by elevating both legs to 33 degrees.

23 FDA-approved NNRTI, bear a cyanovinylphenyl (CVP) group.

24 with patients lying supine; (2) at decreased CVP (CVP-) by inflating blood pressure cuffs to 40 mm Hg

25 but 80% of genes most highly induced during CVP development have reduced expression, suggesting adop

26 With the legs elevated (CVP+), neither mean nor minimum CSA showed any significa

27 ssion (median 32 months versus 15 months for CVP; P < .0001).

28 esponse technology to eight cycles of GP2013-CVP or R-CVP (combination phase), followed by monotherap

29 phamide, vincristine, and prednisone (GP2013-CVP) with rituximab-CVP (R-CVP) in patients with follicu

30 e and 23 [10%] of 231 patients in the GP2013-CVP group and 13 [6%] of 231 patients in the R-CVP group

31 enia (55 [18%] of 312 patients in the GP2013-CVP group and 65 [21%] of 315 patients in the R-CVP grou

32 enia (80 [26%] of 312 patients in the GP2013-CVP group and 93 [30%] of 315 patients in the R-CVP grou

33 se and 17 [7%] of 231 patients in the GP2013-CVP group and nine [4%] of 231 patients in the R-CVP gro

34 ups (289 [93%] of 312 patients in the GP2013-CVP group had an adverse event and 71 [23%] of 312 patie

35 ups (five [2%] of 268 patients in the GP2013-CVP; three [1%] in the R-CVP group).

36 Median PVP was 9.5 (6-17) mm Hg, CVP was 8.5 (6-18) mm Hg, and pulmonary capillary wedge

37 88.9% of those with low, moderate, and high CVP levels, respectively (P<0.0001), at the 18-month con

38 riance (ANOVA) indicated that alterations in CVP were associated with changes in mean CSA (p = 0.03)

39 At FRC, changes in CVP had no significant effect on either mean or minimum

40 y was to test the hypothesis that changes in CVP reflect those in left ventricular filling pressure,

41 These results indicate that changes in CVP significantly alter the response of the upper airway

42 The decrease in CVP with LBNP was correlated with the reduction in PCWP

43 FS+ subjects had the largest decrease in CVP with tilt and had significant increases in MSNA and

44 There were no differences in CVP among all pacing modes (P:=0.27).

45 rend for a decrease in BP and an increase in CVP (P=0.02).

46 ses in SBP, DBP, and MAP and the increase in CVP were significantly less during long-RP tachycardia (

47 strated an abrupt fall in BP, an increase in CVP, and an increase in SNA regardless of the AV interva

48 40 mm Hg on both legs; and (3) at increased CVP (CVP+) by elevating both legs to 33 degrees.

49 Eyes with increased CVP after more severe CRVO demonstrate significantly red

50 However, after leg-cuff inflation (CVP-), highly significant increases in both mean (163 +/

51 significantly higher in patients with lower CVP at all time points (P<0.0001).

52 male piglets and maintaining PPP at 25 mmHg, CVP was measured 3 times at each of 9 levels of airway p

53 ents with the bundle completed received more CVP/Scvo2 monitoring (100.0 vs. 64.8%, p < .01), more an

54 e taste bud cells (TBCs) purified from mouse CVP.

55 While normothermic, CVP was 6.3 +/- 0.2 mmHg and PCWP was 9.5 +/- 0.3 mmHg.

56 Furthermore, the ability of CVP to stratify risk for development of WRF was apparent

57 inspiration (VTei) under three conditions of CVP: (1) at baseline (CVP nl) with patients lying supine

58 domly assigned to receive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159).

59 eas of CNP that correlate with the degree of CVP elevation.

60 ncreased significantly with higher levels of CVP and progressed with time.

61 red by FTT was reduced with higher levels of CVP.

62 Spontaneous lowering of CVP had beneficial effects on BCVA, although this dimini

63 At each study visit, measurements of CVP, best-corrected visual acuity (BCVA), area of CNP, r

64 did not add significantly to the toxicity of CVP.

65 se values provides confidence for the use of CVP in studies assessing ventricular preload during ther

66 signed to eight cycles of R-CVP (n = 159) or CVP alone (n = 162).

67 es of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159).

68 (RVP), but not the caudal ventral pallidum (CVP), were robustly Fos activated during cue-induced rei

69 hich is expressed by circumvallate papillae (CVP) of the mouse tongue, has been implicated in oro-gus

70 clophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -to

71 clophosphamide, vincristine, and prednisone (CVP) in patients with newly diagnosed advanced-stage fol

72 clophosphamide, vincristine, and prednisone (CVP) is one of several standard treatment options for ad

73 clophosphamide, vincristine, and prednisone [CVP]) plus rituximab.

74 clophosphamide, vincristine, and prednisone [CVP]), every 3 weeks during induction, then rituximab ma

75 A low central venous pressure (CVP) (mean threshold <8 mm Hg) was associated with fluid

76 d WRF had a greater central venous pressure (CVP) on admission (18 +/- 7 mm Hg vs. 12 +/- 6 mm Hg, p

77 fects of changes in central venous pressure (CVP) on upper airway size.

78 Central venous pressure (CVP) provides information regarding right ventricular fi

79 muscle SNA, BP, and central venous pressure (CVP) were measured in 14 patients during nitroprusside i

80 lood pressure (BP), central venous pressure (CVP), and heart rate were recorded during 3 minutes of n

81 pressure (BP), ECG, central venous pressure (CVP), and muscle sympathetic nerve activity (MSNA) were

82 lood pressure (BP), central venous pressure (CVP), and peripheral muscle sympathetic nerve activity (

83 lood pressure (BP), central venous pressure (CVP), and SNA were recorded during 3 minutes of right at

84 pressure (PVP) with central venous pressure (CVP), as well as other invasive hemodynamic measurements

85 ), heart rate (HR), central venous pressure (CVP), muscle sympathetic nerve activity (MSNA), and plas

86 pressure (PCWP) and central venous pressure (CVP).

87 rtment: a) initiate central venous pressure (CVP)/central venous oxygen saturation (Scvo2) monitoring

88 Under low airway pressure, CVP did not increase or often decreased when PPP was hig

89 Under high airway pressure, CVP was persistently higher than pneumoperitoneum pressu

90 alyses were performed among airway pressure, CVP, and pneumoperitoneum pressure.

91 e overall response rates for BR and R-CHOP/R-CVP were 97% and 91%, respectively (P = .0102).

92 BR was noninferior to R-CHOP/R-CVP, as assessed by the primary end point of complete re

93 e BR (n = 224) or standard therapy (R-CHOP/R-CVP, n = 223) for 6 cycles; 2 additional cycles were per

94 Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and p

95 rednisone (GP2013-CVP) with rituximab-CVP (R-CVP) in patients with follicular lymphoma.

96 response rates were 88%, 93%, and 91% for R-CVP, R-CHOP, and R-FM, respectively (P=.247).

97 were registered during follow-up: four in R-CVP, five in R-CHOP, and 14 in R-FM.

98 were randomly assigned to eight cycles of R-CVP (n = 159) or CVP alone (n = 162).

99 echnology to eight cycles of GP2013-CVP or R-CVP (combination phase), followed by monotherapy mainten

100 ophosphamide, vincristine, and prednisone (R-CVP).

101 ophosphamide, vincristine, and prednisone [R-CVP]) for treatment-naive patients with indolent non-Hod

102 ailure was 27 months in patients receiving R-CVP and 7 months in the CVP arm (P < .0001).

103 nificantly prolonged in patients receiving R-CVP versus CVP (P < .0001).

104 ive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159).

105 ete response rates were 81% and 41% in the R-CVP arm versus 57% and 10% in the CVP arm, respectively

106 se event; 288 [91%] of 315 patients in the R-CVP group had an adverse event and 63 [20%] had a seriou

107 group and 65 [21%] of 315 patients in the R-CVP group in the combination phase and 17 [7%] of 231 pa

108 group and 93 [30%] of 315 patients in the R-CVP group in the combination phase and 23 [10%] of 231 p

109 group and nine [4%] of 231 patients in the R-CVP group in the maintenance phase).

110 P group and 13 [6%] of 231 patients in the R-CVP group in the maintenance phase).

111 ients in the GP2013-CVP; three [1%] in the R-CVP group).

112 is study, R-CHOP and R-FM were superior to R-CVP in terms of 3-year TTF and PFS.

113 the respective treatment groups (R-CHOP v R-CVP, P=.003; R-FM v R-CVP, P=.006; R-FM v R-CHOP, P=.763

114 ent groups (R-CHOP v R-CVP, P=.003; R-FM v R-CVP, P=.006; R-FM v R-CHOP, P=.763).

115 udy end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit rati

116 FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95% CI, 0.54 to 0.98; P = .037)

117 d to lymphoma progression with R-FM versus R-CVP.

118 ade 3 to 4 neutropenia (64%) compared with R-CVP (28%) and R-CHOP (50%; P< .001).

119 Patients initially treated with R-CVP had a higher risk of lymphoma progression compared w

120 low-up of 30 months, patients treated with R-CVP had a very significantly prolonged time to progressi

121 4-year OS: 83% v 77%;) were achieved with R-CVP versus CVP alone.

122 es demonstrated an improvement in TTP with R-CVP versus CVP irrespective of the Follicular Lymphoma I

123 analyzed 91 untreated patients who received CVP chemotherapy (cyclophosphamide, vincristine, and pre

124 ar lymphoma) evaluable patients who received CVP were randomly assigned to OBS (n = 158) or MR (n = 1

125 , and prednisone (GP2013-CVP) with rituximab-CVP (R-CVP) in patients with follicular lymphoma.

126 or often decreased when PPP was higher than CVP.

127 s embolism increases when PPP is higher than CVP.

128 used to design bicyclic replacements for the CVP group.

129 patients receiving R-CVP and 7 months in the CVP arm (P < .0001).

130 % in the R-CVP arm versus 57% and 10% in the CVP arm, respectively (P < .0001).

131 The addition of rituximab to the CVP regimen significantly improves the clinical outcome

132 During the transition from mesoderm to the CVP, TMEM88 has a chromatin signature of genes that medi

133 -IV follicular lymphoma were assigned 1:1 to CVP plus intravenous infusions of 375 mg/m(2) CT-P10 or

134 se/complete response unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independe

135 in patients with a partial response (PR) to CVP (P < .001).

136 uding OS, confirm the benefit of adding R to CVP in the front-line treatment of FL.

137 prolonged in patients receiving R-CVP versus CVP (P < .0001).

138 83% v 77%;) were achieved with R-CVP versus CVP alone.

139 ated an improvement in TTP with R-CVP versus CVP irrespective of the Follicular Lymphoma Internationa

140 on is correct during thermal challenges when CVP is elevated during skin-surface cooling or reduced d

141 sis iridis was significantly associated with CVP at all time points and was present in 5.6%, 27.9%, a

142 of PVP demonstrates a high correlation with CVP.